Endoluminal Suturing Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Endoluminal Suturing Devices Market Trends and Insights

Rising Prevalence of Obesity and Gastrointestinal Disorders

Global obesity prevalence keeps climbing, producing a steady pipeline of candidates for endoscopic sleeve gastroplasty, transoral fundoplication, and defect-closure procedures. GERD affects roughly one in five adults in Western nations, and many patients seek alternatives to long-term proton-pump inhibitors, fueling procedure demand. In emerging regions, bariatric surgical capacity remains constrained, positioning the endoluminal suturing devices market as an essential bridge therapy. Coupled with chronic GI disorders such as bleeding ulcers and anastomotic leaks, the clinical addressable population is expanding faster than surgical workforce growth. Consequently, payers are studying five-year outcomes indicating durable weight loss and symptom resolution, tilting the benefit-risk calculus toward minimally invasive solutions.

Growing Adoption of Minimally Invasive Endoscopic Procedures

Endoscopic interventions are replacing open or laparoscopic bariatric operations for select patient groups because they shorten recovery, cut complication risk, and leave no external scars. The MERIT randomized trial reported a 13.1-percentage-point improvement in total body weight loss at 12 months with ESG compared to lifestyle therapy, while serious events remained near 2% and no surgical conversions occurred. Professional societies now back ESG for class I–II obesity, citing pooled analysis of more than 15,700 cases with only 1.25% serious events. Hospitals and ambulatory centers are retrofitting suites with dual-channel scopes, high-definition visualization, and advanced suturing systems. The American Society for Gastrointestinal Endoscopy’s STAR Fundamentals of Suturing course, launched in December 2025, is broadening the operator base^{[1]American Society for Gastrointestinal Endoscopy, “STAR Fundamentals of Suturing Course,” asge.org}. Collectively, these trends accelerate procedure migration from operating rooms into flexible endoscopy units, lifting equipment utilization and strengthening the endoluminal suturing devices market.

Technological Advances in Robotics and AI-Guided Suturing

Robotic and AI-assisted platforms are turning technically demanding manual suturing into a digitally guided routine. The da Vinci 5 gained FDA clearance in March 2024, bringing force-feedback to end-effectors that could eventually improve full-thickness gastric plications^{[2]Intuitive Surgical, “Investor Relations and Product Updates,” intuitive.com}. Olympus invested USD 65 million in Swan EndoSurgical in 2025 to develop a flexible robotic suite aiming at a USD 2 billion U.S. opportunity by 2040. KARL STORZ folded Asensus Surgical’s Senhance and LUNA assets into its program in 2024, accelerating performance-guided surgery capabilities. Boston Scientific followed with the OverStitch NXT, adding physician-controlled retractors and better articulation. Early data show these upgrades can shorten procedure times, lower the learning curve, and open new anatomical targets, reinforcing double-digit growth prospects for the endoluminal suturing devices market.

Favorable Reimbursement for ESG and GERD Endotherapy

Economic evidence is convincing payers that endoluminal approaches save money over medication in appropriate patients. A 2024 JAMA analysis found ESG saved USD 33,583 per patient over five years versus semaglutide if the drug stayed at listed prices. Medicare already reimburses transoral incisionless fundoplication under defined criteria, bolstering procedure economics. European health systems reimburse ESG within structured obesity pathways, pushing volumes across Germany, France, and the Nordics. Even so, payer heterogeneity persists; BCBS Rhode Island labeled transoral therapies “not medically necessary” in 2025, illustrating variability that can blunt momentum. Sustained publication of 10-year durability data and head-to-head comparisons with medical therapy will be decisive for long-term market expansion.

High Capital and Procedural Cost of Advanced Systems

An OverStitch console must be paired with specialized endoscopes, while each case typically consumes multiple disposable helixes, cinches, and sutures that can push per-procedure supply costs beyond USD 1,000. Emerging markets and low-volume ambulatory centers find such outlays prohibitive. Manufacturers face rising sterilization compliance fees as the U.S. Environmental Protection Agency tightens ethylene-oxide rules, potentially inflating costs for reprocessed accessories. Medtronic disclosed stapling category price pressure in fiscal 2025, highlighting intensifying competition that constrains pricing flexibility^{[3]Medtronic, “FY25 Earnings Presentation,” medtronic.com}. To defend share, vendors negotiate bundled pricing and volume-based rebates, yet the capital hurdle still slows new program launches and tempers expansion of the endoluminal suturing devices market.

Limited Pool of Skilled Endoscopic Suturing Operators

Advanced suturing demands both cognitive and manual dexterity. Global training programs historically centered on diagnostic rather than therapeutic endoscopy, leaving many regions short of credentialed operators. ASGE’s STAR course addresses the gap in the United States, but Asia-Pacific and Latin America still lag in simulation centers and proctorships. Specialty fragmentation compounds the problem; gastroenterologists, not surgeons, perform most ESG cases, causing under-representation in surgical registries and limiting peer-to-peer diffusion. KARL STORZ’s acquisition of Asensus aims to embed haptic feedback and step-wise guidance into devices, lowering the learning threshold. Until those platforms achieve broad rollout, operator scarcity will cap procedure volumes in many hospitals, restraining the endoluminal suturing devices market.

Segment Analysis

By Product Type: Single-Use Dominance Amid Robotic Platform Acceleration

Single-use devices captured 57.55% of 2025 revenue, reflecting hospital infection-control rules that discourage reprocessing and a manufacturer pivot toward predictable consumable streams. Disposable helixes, cinches, and cartridges often account for most per-case spend and underpin attractive gross margins within the endoluminal suturing devices market. Reusable consoles face sterilization bottlenecks as EPA rules tighten ethylene-oxide emissions, raising compliance costs and nudging buyers toward disposables or semi-automated kits. 

Parallel to this consumable upswing, fully automated and robotic suites are charting the fastest growth, with a projected 14.25% CAGR through 2031, as Olympus-Swan and KARL STORZ-Asensus alliances funnel capital into force-feedback actuators and vision-guided stapling. Boston Scientific’s OverStitch NXT shows how incremental enhancements—an auxiliary irrigation channel and larger plication bites—extend the life of manual platforms while the market digests premium robotic options. Emerging through-the-scope devices such as EndoZip promise lower capital thresholds by eliminating external consoles, potentially expanding addressable sites among community hospitals and ambulatory centers. Over the forecast horizon, product segmentation is likely to stratify into premium robotics, mid-range semi-automated scopes, and cost-conscious single-use kits, each aiming at distinct volume bands and case-complexity tiers in the endoluminal suturing devices market.

Note: Segment shares of all individual segments available upon report purchase

By Application: Gastrointestinal Surgery Leads as GERD Procedures Accelerate

Gastrointestinal surgery procedures—including endoscopic sleeve gastroplasty, defect closure, and revisional outlet reduction—generated 44.53% of revenue in 2025 and continue to anchor the endoluminal suturing devices market size. Bariatric centers gravitate toward suturing because it enables durable gastric remodeling with fewer complications than stapling. Meanwhile, GERD interventions are on a steeper 12.85% CAGR trajectory, buoyed by five-year TEMPO data showing 86% regurgitation elimination and payer coverage expansions for transoral fundoplication. 

Commercial payers remain mixed; BCBS Rhode Island’s 2025 denial contrasts with Medicare’s defined coverage, but growing registry evidence—94% clinical success and 72% acid-exposure normalization—strengthens the reimbursement case. Elsewhere, bleeding control, anastomotic leak repair, and post-ESD mucosal closure offer incremental growth pockets where sutures compete head-to-head with clips and sealants. Overall, the application mix is shifting toward GERD and revision heavy caseloads, yet bariatric sleeve applications will sustain leadership through 2031, supporting volume resilience across diverse care settings within the endoluminal suturing devices market.

By End User: Hospitals Retain Share as Ambulatory Centers Gain Momentum

Hospitals maintained 49.23% of global revenue in 2025 thanks to established bariatric programs, multidisciplinary teams, and capital budget cycles aligned with device acquisition. Nevertheless, ambulatory surgical centers (ASCs) are pacing at a 12.55% CAGR, fueled by site-neutral Medicare payments and patient preference for same-day discharge. ASCs leverage lower facility fees and simplified scheduling to attract ESG and fundoplication patients, amplifying device turnover. 

Specialty clinics and retail health providers are layering concierge nutrition support and transparent bundle pricing onto ESG offerings, further decentralizing patient flow from tertiary centers. Research institutes, though small in revenue, remain vital for multicenter trials that validate next-gen robotics and AI guidance. Over the forecast window, hospitals will still lead complex revision and full-thickness cases, but ASCs will outpace them in volume growth, diversifying the customer base for the endoluminal suturing devices market.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America generated 41.25% of 2025 revenue, benefiting from early FDA clearances, extensive bariatric-endoscopy training networks, and Medicare reimbursement for select anti-reflux and bariatric procedures. The region’s health systems have the infrastructure to integrate robotics rapidly, and strategic acquisitions—such as KARL STORZ-Asensus—bolster technology pipelines that will feed future adoption. Yet Asia-Pacific is on track for a 13.21% CAGR through 2031. China’s National Medical Products Administration cleared Intuitive’s Ion system in 2024, and Japanese regulators approved multiple suturing accessories in 2025, positioning regional endoscopy leaders to localize Western platforms. 

Rising middle-class demand for metabolic surgery, combined with hospital partnerships that co-develop training curricula, accelerates uptake. Europe, while modest in headline growth, maintains a solid installed base, supported by unified technical guidance from ESGE and state-funded reimbursement across Germany, France, and the Nordics. Central and Eastern European markets add upside as they adopt ESG within national obesity strategies. Latin America and the Middle East present mixed pictures; private payers drive premium uptake in the Gulf Cooperation Council, whereas public budgets in Brazil and Mexico restrict volume to high-income urban areas. Overall, the geography mix will tilt gradually toward Asia-Pacific without dislodging North America from revenue leadership, ensuring a balanced demand profile for the endoluminal suturing devices market.